Compare Freshworks Inc (FRSH) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs Gilead Sciences, Inc. — how do they compare? Freshworks Inc trades at $13.79 (market cap $3.56B), while Gilead Sciences, Inc. trades at $149.66 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 51.2× Freshworks Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Freshworks Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Freshworks Inc for 39 Days and Gilead Sciences, Inc. for 111 Days on average.
| FRSH | GILD | |
|---|---|---|
Market Cap | $3.56B | $182.40B |
Volume | 9,066,454 | 4,469,821 |
Sector | Technology | Health |
52-Week High | $13.92 | $155.80 |
52-Week Low | $6.88 | $116.74 |
Typical Hold Time | 39 Days | 111 Days |
Enterprise Value | $2.93B | $205.46B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $13.60, down 1.16% on the day, with a bullish technical outlook from moving averages. The company reported strong Q2 2026 results, beating earnings estimates with EPS of $0.17 versus $0.13 expected, and achieved its first quarter of GAAP profitability. Revenue growth remains robust at 16% year-over-year, supported by strength in its employee experience portfolio and AI adoption.
The investment outlook is positive, driven by sustained revenue growth, improving profitability, and a favorable analyst consensus with a $14.60 price target. Key risks include high valuation multiples like a 43.89 EV/EBITDA and competitive pressures in the SaaS sector. The stock presents an opportunity for rerating if profitability trends continue.
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
